← Eichor
Condition: Diffuse Large B Lymphoma Dlbcl Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Diffuse Large B Lymphoma Dlbcl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07078500Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07494565Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
EARLY_Phase 1 · 1 location(s) · He Huang · NCT06120166Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L
Phase 2 · 23 location(s) · Xynomic Pharmaceuticals, Inc. · NCT03936153The CARDIOPROTECT Trial
Phase 2 · 1 location(s) · Beth Israel Deaconess Medical Center · NCT07654426AGMT Austrian Lymphoma Registry
Phase N/A · 1 location(s) · Arbeitsgemeinschaft medikamentoese Tumortherapie · NCT06294652This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · 6 location(s) · LTZ Therapeutics, Inc. · NCT07121946Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Phase N/A · 1 location(s) · Ain Shams University · NCT07057765CR-CHOP+X in Previously Untreated DEL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06701357Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, a
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07608978Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06043011Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refracto
Phase 2/Phase 3 · 135 location(s) · Merck Sharp & Dohme LLC · NCT05139017Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Phase N/A · 4 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT04300101Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06803693CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07397832Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Phase 2 · 11 location(s) · Sun Yat-sen University · NCT06647940ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
NA · 1 location(s) · Hua-Jay J Cherng, MD · NCT06693830A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · 168 location(s) · Regeneron Pharmaceuticals · NCT06091865IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLB
Phase 2 · 1 location(s) · Danielle Wallace · NCT06828991Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large
Phase 1 · 2 location(s) · The University of Texas Health Science Center at San Antonio · NCT06977711A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06765317Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Phase 1 · 9 location(s) · National Cancer Institute (NCI) · NCT05272384A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06736613Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
NA · 1 location(s) · Tata Memorial Hospital · NCT02964858Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Phase 2 · 1 location(s) · Huazhong University of Science and Technology · NCT06005870
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.